View Author
patient treatment depression study effect side effects cancer change baseline symptom ifn-a group activity van gool ar depressive pagina interferon concentration disorder kanker 8 weeks level tryptophan month ratio bannink 20-12-2005 bannink m control melanoma scale psychiatry plasma melanoma patients score 4 weeks ifn-alfa increase therapy control group hepatitis c cytokine range kruit whj bedrijfsart anxiety hepatitis kankerpatien platelet platelet mao activity 6 months women rating research result worden parameter fekke van gool decrease cancer patients interferon-alpha depressive symptoms metabolism eggermont amm oncology wordt blood sample behandeling synthesis erasmu kruit interferon-alfa patien stoter g system onderzoek table terugkeer
10 Most Recent Publications
|
Higher doses of opioids in patients who need palliative sedation prior to death: Cause or consequence?
(Article)
Oosten, A.W. Oldenmenger, W.H. Zuylen, C. van Schmitz, P.I.M. Bannink, M. Lieverse, P.J. Bromberg, J.E.C. Rijt, C.C.D. van der |
2011-10-01
|
|
Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-a therapy
(Article)
Fekkes, D. Gool, A.R. van Bannink, M. Sleijfer, S. Kruit, W.H.J. Holt, B. van der Eggermont, A.M.M. Hengeveld, M.W. Stoter, G. |
2009-10-01
|
|
The Distress Thermometer assessed in women at risk of developing hereditary breast cancer
(Article)
Dooren, S. van Duivenvoorden, H.J. Passchier, J. Bannink, M. Tan, M.B.M. Oldenmenger, W.H. Seynaeve, C.M. Rijt, C.C.D. van der |
2009-10-01
|
|
Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-α: Course and relationship with psychiatric status
(Article)
Gool, A.R. van Verkerk, R. Hengeveld, M.W. Fekkes, D. Bannink, M. Sleijfer, S. Kruit, W.H.J. Holt, B. van der Scharpé, S. Eggermont, A.M.M. Stoter, G. |
2008-10-01
|
|
Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-α in patients with renal cell carcinoma
(Article)
Gool, A.R. van Verkerk, R. Hengeveld, M.W. Fekkes, D. Sleijfer, S. Bannink, M. Kruit, W.H.J. Holt, B. van der Scharpé, S. Eggermont, A.M.M. Stoter, G. |
2008-05-01
|
|
Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated
(Article)
Bannink, M. Kruit, W.H.J. Gool, A.R. van Sleijfer, S. Holt, B. van der Eggermont, A.M.M. Stoter, G. Hengeveld, M.W. |
2008-01-01
|
|
Werkhervatting bij kanker: wetenschappelijk onderbouwd
(Article)
Zanten-Przybysz, I. van Boer, A.G.E.M. de Berge, E.E. ten Uitterhoeve, A.L.J. Bannink, M. Gijsen, B.C.M. Vreugdenhil, G. |
2008-01-01
|
|
Interferon-α influences tryptophan metabolism without inducing psychiatric side effects
(Article)
Bannink, M. Fekkes, D. Gool, A.R. van Kruit, W.H.J. Sleijfer, S. Holt, B. van der Eggermont, A.M.M. Stoter, G. Hengeveld, M.W. |
2007-10-01
|
|
Changes in and correlates of individual quality of life in advanced cancer patients admitted to an academic unit for palliative care
(Article)
Echteld, M.A. Zuylen, L. van Bannink, M. Witkamp, E. Rijt, C.C.D. van der |
2007-06-27
|
|
Influence of pegylated interferon-α therapy on plasma levels of citrulline and arginine in melanoma patients
(Article)
Fekkes, D. Bannink, M. Kruit, W.H.J. Gool, A.R. van Mulder, P.G.H. Sleijfer, S. Eggermont, A.M.M. Stoter, G. |
2007-01-01
|
